Study Unveils Complexities of BP Management with Bruton’s Tyrosine Kinase Inhibitors in Lymphoid Malignancies

In a groundbreaking study, researchers
have delved into the optimal approaches for managing hypertension (HTN) in
patients undergoing Bruton’s tyrosine kinase inhibitor (BTKi) treatment, a
revolutionary therapy for lymphoid malignancies. They found that managing HTN in patients undergoing BTKi
treatment can be complex and may necessitate multiple anti-hypertensive
medications.


The
study results were published in the journal Blood Advances.  


While BTKis, such as ibrutinib, have
proven to be generally well-tolerated and less toxic than traditional
chemotherapy options, this research sheds light on the potential challenge of
new or worsening HTN associated with their use.

While Bruton’s tyrosine kinase
inhibitors (BTKis) are typically well-tolerated and exhibit lower toxicity
compared to chemotherapy options for lymphoid malignancies, notable concern
arises as BTKis, including ibrutinib, may trigger the onset or exacerbation of
hypertension (HTN).

The optimal management of HTN associated with BTKis remains
a relatively unexplored territory.

The study, which included 196 patients
with lymphoid malignancies on BTKis and concurrent anti-hypertensive
medications, aimed to identify effective strategies for blood pressure
management. Patients were categorized into two groups based on their HTN status:
those with pre-existing hypertension before starting BTKi treatment (prior-HTN)
and those who developed HTN after initiating BTKi therapy (de novo HTN).

The
analysis considered patients with a minimum of 3 months of follow-up data.

Using generalized estimating
equations, the researchers explored the associations between time-varying mean
arterial pressures (MAPs) and different anti-hypertensive drug categories.

Findings:

  • Among the significant findings, 118 patients had prior-HTN, while 78 developed
    de novo HTN.
  • Notably, patients with prior HTN
    experienced a statistically significant mean MAP reduction when taking a
    combination of beta blockers (BBs) with hydrochlorothiazide (HCTZ), showing a
    reduction of -5.05 mmHg (95% CI -10.0 to -0.0596; p = 0.047).
  • Similarly, patients with de novo HTN
    exhibited a significant MAP reduction when prescribed either an
    angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor
    blocker (ARB) with HCTZ, demonstrating a reduction of -5.47 mmHg (95% CI -10.9 to
    -0.001; p = 0.05).

  • These regimens were also associated
    with the highest percentages of normotensive MAPs.


  • The study’s findings suggest that
    managing HTN in patients undergoing BTKi treatment is intricate and may require
    a multifaceted approach involving multiple anti-hypertensive medications.
  • For
    patients with prior-HTN, combination regimens with BBs and HCTZ appeared to be
    beneficial, while those with de novo HTN showed improved outcomes with
    ACEi/ARBs combined with HCTZ.

The researchers underscore the importance of
further prospective studies to validate these encouraging results.

This breakthrough study not only
enhances our understanding of blood pressure management in the context of
cutting-edge lymphoid malignancy treatments but also underscores the critical
need for personalized approaches to ensure the well-being of patients
navigating these innovative therapeutic landscapes. 

Further reading: Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Doi: https://doi.org/10.1182/bloodadvances.2023011569

Powered by WPeMatico

Silver diamine fluoride additional tool for addressing dentine hypersensitivity and improving QoL of patients, states study

Silver diamine fluoride additional tool for addressing dentine hypersensitivity and improving QoL of patients states a study published in the Journal of Dentistry.

A study was done to assess the clinical evidence for silver diamine fluoride (SDF) to reduce dentine hypersensitivity in adults. Two independent researchers searched the English literature in five databases (Scopus, PubMed, Web of Science, EMBASE and the Cochrane Library) up to 15th July 2023 for clinical trials investigating the desensitising effect of professionally applied SDF to manage dentine hypersensitivity in adults aged 18 or above at any follow-up period. The primary outcome was the change in dentine hypersensitivity between baseline and follow-up visits after SDF application regarding any validated pain outcome measures. The Cochrane guidelines were used for the risk of bias assessment.

Results: Three hundred and thirty-one studies were identified, and four of them were finally included. Three of the included studies were rated as having a ‘low risk’ of bias. The SDF solution reduced dentine hypersensitivity in adults. The percentage reduction in dentine hypersensitivity ranged from 23 % to 56 % after a single application of SDF solution. Moreover, the SDF solution was more effective than potassium nitrate, potassium oxalate and glutaraldehyde plus hydroxyethyl methacrylate in reducing dentine hypersensitivity. Meta-analysis indicated a more significant reduction in visual analogue scales (1–10) by 1.35 (95 % CI:0.9–1.8; p<0.00001) after receiving the SDF application than controls. The included clinical trials showed that SDF solution reduced dentine hypersensitivity in adults. However, clinical trials are few, and their protocol varied from one another. Further well-designed clinical trials should be conducted to provide more evidence on its use to manage dentine hypersensitivity. SDF is cleared as desensitizing agents by the US Food and Drug Administration to manage dentine hypersensitivity, which induces pain, limits food choice, and impacts the quality of life. Evidence from this systematic review informs clinicians and provides researchers insight for future research on SDF use for dentine hypersensitivity.

Reference:

Alice Kit Ying Chan, Yiu Cheung Tsang, Ollie Yiru Yu, Edward Chin Man Lo, Katherine Chiu Man Leung, Chun Hung Chu. Clinical evidence for silver diamine fluoride to reduce dentine hypersensitivity: A systematic review. Journal of Dentistry, Volume 142, 2024, 104868. ISSN 0300-5712, https://doi.org/10.1016/j.jdent.2024.104868. (https://www.sciencedirect.com/science/article/pii/S0300571224000381)

Keywords:

Silver diamine fluoride, additional tool, dentine hypersensitivity, QoL of patients, Journal of Dentistry, Silver diamine fluoride; Dentine hypersensitivity; Oral health; Caries; Older adult, Alice Kit Ying Chan, Yiu Cheung Tsang, Ollie Yiru Yu, Edward Chin Man Lo, Katherine Chiu Man Leung, Chun Hung Chu

Powered by WPeMatico

Increased retinal detachment risk observed among vitiligo patients: Study

Vitiligo is a condition characterized by the loss of skin pigment and has long been known to be associated majorly with various ocular abnormalities. A recent study from Taiwan explored a concerning association between vitiligo and retinal detachment (RD). The key findings of this studywere published in the journal of Clinical and Experimental Dermatology.

The study was conducted as a nationwide population-based cohort study in Taiwan that analyzed data from the Taiwan National Health Insurance Database from 2007 to 2018. This study identified a cohort of 21,132 vitiligo patients and matched them in a 1:4 ratio with non-vitiligo patients based on age, sex and propensity score of comorbidities.

The findings of the study were;

The vitiligo cohort expressed a significantly higher rate of retinal detachment when compared to the non-vitiligo cohort. After adjusting for various factors, including age, sex and comorbidities, the research found that vitiligo patients underwent a 1.44-fold increased risk of retinal detachment.

Also, the vitiligo patients who required treatments such as phototherapy, systemic corticosteroids or immunosuppressants showed an even greater risk, with a marked 1.57-fold increase in retinal detachment risk.

This study emphasized the importance of these findings which highlights the need for increased vigilance among healthcare professionals regarding the ocular health of vitiligo patients. It’s crucial that clinicians consider the potential risk of retinal detachment in these patients who undergo specific treatments.

With vitiligo affecting approximately 1% of the global population, the clear understanding of its potential systemic associations is critical for comprehensive patient care. Thereby, the comprehensive analysis of study that was over a 10-year follow-up period, further solidifies the observed association between vitiligo and retinal detachment.

Reference:

Chen, C.-L., Wu, C.-Y., Chen, Y.-L., Chen, C.-C., Chang, Y.-T., & Wu, C.-Y. (2024). Association between vitiligo and risk of retinal detachment: A population-based cohort study in Taiwan. In Clinical and Experimental Dermatology. Oxford University Press (OUP). https://doi.org/10.1093/ced/llae035

Powered by WPeMatico

Which Antibiotics Best Prevent Infections for Children With Vesicoureteral Reflux?

Children with vesicoureteral reflux often need to take continuous antibiotics to reduce the risk of urinary tract infections (UTIs). But which antibiotics do the best job at preventing these infections?

Researchers in the Division of Urology at Children’s Hospital Los Angeles recently conducted a study to shed more light on this issue. The results were presented in recently at the Societies for Pediatric Urology Congress in Houston.

“This is a complex question because we know that antibiotic resistance patterns are variable, based on region and many other factors,” says Scott Sparks, MD, a pediatric urologist at CHLA who led the study. “We wanted to see if we could identify any definitive trends about antibiotic effectiveness for our patients here in Los Angeles.”

Key findings

Vesicoureteral reflux is typically a congenital condition in which urine flows backward from the bladder to the ureters or kidneys. Reflux commonly resolves on its own as children grow. But until that happens, some patients may benefit from continuous low-dose antibiotic therapy to prevent UTIs.

The retrospective study examined how often these patients have breakthrough UTIs. The study included 402 children with reflux who were seen at CHLA from 2015 to 2021. All the patients were on continuous antibiotic therapy.

The study found that:

  • Patients taking cephalexin had the highest rates of breakthrough UTIs, at 2.52 per 100 person months.
  • Patients taking sulfamethoxazole/trimethoprim also had relatively high rates of infections, at 1.52 per 100 person months.
  • A large percentage of breakthrough UTIs were resistant to both cephalexin and sulfamethoxazole/trimethoprim.
  • Nitrofurantoin had the lowest rates of breakthrough UTIs.

Guiding discussions with families

Dr. Sparks cautions that these findings are specific to the Los Angeles area. Breakthrough rates are also just one factor in deciding on the best antibiotic for a particular patient.

For example, while nitrofurantoin had the lowest rates of infections, it can be difficult for parents to administer. The medicine does not come in a liquid, and because patients with reflux are typically very young, capsules must be opened up and sprinkled on food.

“I think the biggest take-home message is that, while there’s no perfect choice, it’s important for physicians to be aware of the antibiotic resistance patterns in their own community,” Dr. Sparks says.

“I haven’t significantly changed my prescribing patterns based on these findings,” he adds. “But it has helped me have better discussions with families. I can give them more specific data now about each medicine and what they can expect. Then together, we can make the best choice for each child.”

Powered by WPeMatico

Disruption of multiple complement proteins linked to development of islet autoimmunity and type 1 diabetes: Study

A recent study published in the journal of iScience explored the important role of the complement system in the early stages of Type 1 Diabetes (T1D) which could potentially pave the way for improved detection and prevention strategies. Type 1 diabetes is a chronic condition which affects millions worldwide and is characterized by the autoimmune destruction of insulin-producing pancreatic β cells. 

This recent study conducted by the team of Bobbie-Jo Webb-Robertson highlighted the significance of gene-environment interactions in initiating the autoimmune response that leads to T1D. Also, this study reveals that disruptions in the complement system precede the appearance of islet autoantibodies which indicate autoimmunity in T1D patients.

The complement system is a complex network of proteins involved in immune responses that appears to play a crucial role in the pathogenesis of T1D. The research analyzed samples from children at risk of developing T1D and observed lower levels of complement proteins in those who progressed to clinical T1D when compared to the individuals who did not.

These findings suggest that monitoring complement protein levels could be a valuable biomarker for predicting the onset of T1D and potentially intervening to prevent the progression. Targeting the complement pathway could offer new therapeutic options for managing and potentially slowing down or stopping the development of T1D. The outcomes emphasized the significance of the complement system that represents an understudied but promising target to understand and combating the Type 1 Diabetes.

Reference:

Webb-Robertson, B.-J. M., Nakayasu, E. S., Dong, F., Waugh, K. C., Flores, J. E., Bramer, L. M., Schepmoes, A. A., Gao, Y., Fillmore, T. L., Onengut-Gumuscu, S., Frazer-Abel, A., Rich, S. S., Holers, V. M., Metz, T. O., & Rewers, M. J. (2024). Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes. In iScience (Vol. 27, Issue 2, p. 108769). Elsevier BV. https://doi.org/10.1016/j.isci.2023.108769

Powered by WPeMatico

International Study Finds Thrombectomy Highly Effective Long-Term Treatment for Large Strokes

In a major, international study, named SELECT2, a University Hospitals (UH) research team found that patients with large strokes had a dramatically better recovery after endovascular thrombectomy plus medical management at long-term follow-up, than patients who only received standard medical management.

Endovascular thrombectomy is mechanical recovery of a clot that is blocking blood flow in an artery. Size of a stroke is determined by the range of damaged brain tissue seen through CT or MRI scans. While thrombectomy has proven effective in smaller strokes, patients with large strokes have been considered too high risk for the procedure.

The SELECT2 study was a tremendous, global team effort, spearheaded by UH as the coordinating center. A total of 352 patients, ages 18 to 85, with large ischemic strokes were randomized at 31 hospitals in North America, Europe, Australia and New Zealand. The primary findings of SELECT2 trial were published last year in the New England Journal of Medicine, demonstrating better clinical outcomes in patients receiving thrombectomy at the 90-day follow-up. Those findings, along with other trials, established efficacy and safety of endovascular thrombectomy in patients with large core strokes.

However, long-term outcomes for these patients were not explored before. As these patients have suffered large strokes, it remains plausible that they will take a longer time to achieve optimal stroke outcomes. The SELECT2 research team opted to address this question and analyzed patient outcomes after one year. The study published today in The Lancet to coincide with its presentation at the International Stroke Conference (ISC 2024) in Phoenix.

Patients receiving thrombectomy procedure demonstrated close to three times higher rates of independent living and twice the rates of independent walking. For every six patients treated, one achieved better outcomes as compared to medical management only. For a comparison, balloon angioplasty for heart attack only benefits one in 20-50 patients. Patients also demonstrated better quality of life scores.

Global Principal Investigator and Lead Author of the study, Amrou Sarraj, MD, said, “Throughout our research and clinical trials over the past three years, we’ve established that endovascular thrombectomy for patients with large ischemic stroke is safe and effective. However, until now, long-term outcomes for these patients remained widely unknown.” Dr. Sarraj is also the Stroke Center and System Director, the George M. Humphrey II Chair in Neurology at University Hospitals, and Professor of Neurology at Case Western Reserve University School of Medicine.

The SELECT2 results represent a major advancement in stroke therapy worldwide, and will bring hope for patients and families in a subgroup of patients who previously would have been thought not to benefit. The study proved that a higher quality of life for these patients persists for at least one year following intervention.

“Now that we have been able to follow these patients for a full year, we have confirmed the long-term benefits of thrombectomy in patients with large core strokes,” Dr. Sarraj explained. “With the evidence that improvement continues, exploration of how we can further improve these outcomes, including efforts on supportive care, such as rehabilitation and adjunctive therapies, becomes very important.”

“University Hospitals is thrilled to have served as the coordinating site for the transformative, international SELECT2 study expanding the indications for thrombectomy in large strokes,” said Daniel Simon, MD, President, Academic & External Affairs, Chief Scientific Officer, and Ernie and Patti Novak Distinguished Chair in Health Care Leadership at University Hospitals. “The results of this study will impact thousands of patients worldwide, significantly improving their quality of life. We look forward to implementing this practice changing treatment for stroke in our health system.” Dr. Simon is also Professor of Medicine and Senior Associate Dean for Academic Affairs at Case Western Reserve School of Medicine.

Reference:

Amrou Sarraj, Ameer E. Hassan, Michael G. Abraham, Santiago Ortega-Gutierrez, Scott E. Kasner, M. Shazam Hussain, Michael Chen, Spiros Blackburn, Clark W. Sitton, Leonid Churilov, Sophia Sundararajan, Trial of Endovascular Thrombectomy for Large Ischemic Strokes,New England Journal of Medicine, DOI: 10.1056/NEJMoa2214403.

Powered by WPeMatico

DMER Maharashtra Invites Online Applications for Bond Service allotment to Super-Speciality degree holders Summer-2023 Batch, details

Maharashtra: The Directorate of Medical Education & Research (DMER Maharashtra) has invited Online Applications and online allotment of Government Bond Service to Super-Speciality degree holders of Summer-2023 Batch.

The notice states, “As per the Government Resolution No. WPM 1011/CR 352/ll/Edu-2, dated 4th April 2012 the Central Committees has been constituted. The Process of Central round for allotment of bond services to Super Speciality candidates will be carried out by filling online application form and by online allotment as per following schedule. The concerned should note Department wise & Speciality wise available vacant posts being published on DMER website.”

Schedule for Online Application and Online Allotment

Date

Time

Speciality

22.02.2024 to 26.02.2024

from 11.00 am to upto 5.00 pm

Filling of online application form and
online Choice filling process

27.02.2024

after. 5.00 pm.

Declaration of allotment of bond service to
candidate and issue of recommendation letter from web portal through Login ID

Qualification required for Super Speciality Medical Officer – Superspeciality in specific subject.

Note:

All detail information including the number of available vacant posts, eligibility criteria, tie-breaker for selection, list of documents required to be submitted to the institutes will be published on DMER’s website  on 21.02.2024

All eligible candidates must fill online application form on DMER’s website.

Vacancy position of posts is likely to change anytime.

List of eligible candidates for allotment of bond services is available on DMER’s website with the information.

Instructions to the candidates

A) General Instructions :

1. Candidates will be allotted seats as per subject merit for posts of Assistant Professor, Super Speciality Medical Officer, Senior Resident on post in Superspeciality on the basis of marks obtained in Superspeciality degree examination. All posts will be allotted on merit basis as Open Category.

2. All candidates who are eligible for getting bond service as per list attached must fill online application form.

3. If any candidate doses not fill online application form there by refusing to get allotment of bond service, the said candidate will be deemed to be not interested to comply bond service. Hence for such candidate the process of recovery of bond penalty amount will be initiated.

4. Recommendation /Selection will be displayed on DMER website on 26.02.2024

5. Candidate can download Recommendations letter from DMER website www.dmerbond.org through Login ID

6. Candidates should take print out of recommendation letter and report to concerned allotted institute with requisite documents within 7 days from the date of recommendation letter.

7. Helpline Number – 022 22652193, Time 10.00 am to 05.45 pm. strictly.

B) The candidate must submit attested photo copy of requisite documents at respective institute where they will be allotted post as per the list given below:

a) SSC Passing Certificate / valid passport (as proof of age).

b) Superspeciality mark-sheets

c) Degree Mark sheet / Grade Certificate

d) Attempt certificate of all MBBS, MD/MS examinations from the head of the institution.

e) MBBS degree / Passing certificate.

f) MD/M.S. Degree Passing Certificate.

g) Permanent Registration certificate of Maharashtra Medical Council or other State Medical Councils in India/MCI.

h) Online recommendation letter of allotment of bond service, (will be mailed to the candidates on their registered email id)

C) Rule of TIE-BREAKER:

Selection of candidate for the vacant post shall be as per the procedure of preparation of merit list as given below.

First Level:-The Candidate having Highest Mark in DM/MCH postgraduate examination (Superspeciality) will be preferred, ‘

if tie persists then –

Second Level: – The Candidate having Highest aggregate Mark in final MD / MS will be preferred,

if tie persists then –

Third Level: – The Candidate having Highest Mark in Final MBBS will be preferred,

if tie persists then –

Fourth Level: – The older candidate will be preferred

To view the official Notice, Click here : https://medicaldialogues.in/pdf_upload/super-notification-232930.pdf

Powered by WPeMatico

Avid appetite in childhood linked to later eating disorder symptoms

The Lancet Child & Adolescent HealthAn enthusiastic response to food in early childhood may be linked to a higher likelihood of experiencing eating disorder symptoms in adolescence, according to a new study led by researchers at UCL and Erasmus University Rotterdam.

The study, published in The Lancet Child & Adolescent Health, looked at survey data from 3,670 young people in the UK and the Netherlands to investigate how appetite traits in early childhood might relate to the likelihood of developing eating disorder symptoms up to 10 years later.

The researchers found that a particularly high food responsiveness, defined as the urge to eat when you see, smell or taste palatable food, at the ages of four and five was linked to a higher likelihood of reporting a range of eating disorder symptoms at ages 12 to 14.

The team also found that a slower pace of eating and feeling full more quickly (high sensitivity to satiety) in early childhood may be protective against developing some eating disorder symptoms later.

Co-lead author Dr Ivonne Derks (UCL Institute of Epidemiology & Health Care) said: “Although our study cannot prove causality, our findings suggest food cue responsiveness may be one predisposing risk factor for the onset of eating disorder symptoms in adolescence.

“However, high responsiveness to food is also a normal and very common behaviour and should be seen as just one potential risk factor among many rather than something to cause parents worry.”

Higher food responsiveness was linked to a 16% to 47% increase in the odds of reporting eating disorder symptoms, including binge eating symptoms, uncontrolled eating, emotional eating, restrained eating and compensatory behaviours.

The 47% increase was found for binge eating symptoms (eating a very large amount of food and/or experiencing the feeling of loss of control over eating), meaning that adolescents whose parents rated them highest on food responsiveness were almost three times more likely to report binge eating symptoms compared to adolescents whose parents scored them lowest.

A 16% increase in odds was found for restrained eating, whereby a person restricts their intake of food to lose weight or avoid weight gain.

Just like food responsiveness, emotional overeating in early childhood was also linked with higher odds of engaging in compensatory behaviours, which are intended to avoid weight gain, such as skipping meals, fasting and excessive exercise.

In turn, some appetite traits seemed to be protective against developing eating disorder symptoms later. Higher satiety responsiveness – that is, feeling full more quickly after eating, and feeling full for longer – was linked to lower odds of uncontrolled eating (defined as the extent to which someone feels out of control and eats more than usual) and compensatory behaviours.

A slower pace of eating, meanwhile, was linked to lower odds of compensatory behaviours and restrained eating.

The researchers also found that appetite traits such as food fussiness, emotional undereating (eating less due to low mood), and enjoyment of food in early childhood were not linked to later eating disorder symptoms in adolescence.

For the study, the researchers looked at data from two separate longitudinal studies: Generation R, following children born in Rotterdam, the Netherlands, between 2002 and 2006, and Gemini, which follows twins born in England and Wales in 2007.

Appetite traits were assessed based on parents’ questionnaire responses when the children were aged four or five. Eating disorder symptoms were self-reported by the then adolescents themselves at ages 12 to 14, when eating disorder symptoms typically start to emerge.

About 10% of the adolescents reported binge eating symptoms, where people eat an unusual amount of food and/or experience the feeling of loss of control over eating. Next to that, 50% reported at least one behaviour to compensate their food intake or to avoid gaining weight, such as skipping a meal.

Co-senior author Dr Clare Llewellyn (UCL Institute of Epidemiology & Health Care) said: “While the role of appetite in the development of obesity has been studied for many decades, this is the first study to comprehensively examine the role of appetite traits in the development of eating disorder symptoms.

“Eating disorders can be harder to treat effectively once they develop and so it would be better to prevent them from occurring in the first place. Our work in identifying risk factors in early life aims to support the development of possible prevention strategies. These could, for instance, involve providing extra support to children at higher risk.”

Appetite traits indicate how we respond to food and the opportunity to eat, and the extent to which we want to eat more or less when experiencing negative emotions. They are divided into food approach appetitive traits (e.g. food responsiveness, enjoyment of food, emotional overeating) and food avoidance traits (e.g. satiety responsiveness, food fussiness, slowness in eating, emotional undereating).

Co-senior author Professor Pauline Jansen of Erasmus University Rotterdam said: “Overall, our findings suggest that developing and testing prevention strategies may be a worthwhile effort. Although appetite has a substantial genetic component, we also know that there are environmental influences that offer opportunities for behaviour change.”

The researchers indicate that a healthy food environment and responsive parental feeding strategies may help to lower the risk of developing eating disorders.

Co-lead author Dr Zeynep Nas (UCL Institute of Epidemiology & Health Care) explained: “A healthy food environment is an environment in which healthy foods are available and more prominent, salient and affordable than less healthy options. This also includes wider access to food such as what types of food outlets are available in our neighbourhood and what food we see on TV.

“Responsive feeding is about providing nutritious food at set mealtimes and snack times, and then allowing the child to decide what to eat and how much to eat (if anything at all) without pressuring them.”

In a separate paper, accepted for publication in the International Journal of Eating Disorders, a similar research team looked at the same two cohorts, Generation R and Gemini, to investigate how parental feeding practices in early childhood might affect likelihood of eating disorder symptoms in adolescence.

The researchers found that non-responsive feeding practices, such as putting pressure on children to eat or using food as a reward or to soothe emotions, were linked to a higher likelihood of specific eating disorder symptoms later. However, the associations were small and varied between the two cohorts, and the researchers said further replication studies were needed.

Reference:

vonne P M Derks, Zeynep Nas, Holly A Harris, Alice R Kininmonth, Prof Janet Treasure, Prof Pauline W Jansen, Early childhood appetitive traits and eating disorder symptoms in adolescence: a 10-year longitudinal follow-up study in the Netherlands and the UK, The Lancet Child & Adolescent Health, DOI:https://doi.org/10.1016/S2352-4642(23)00342-5.

Powered by WPeMatico

Newborn’s skin peels after being dipped in hot water: Consumer Court holds medical negligence, slaps Rs 10 lakh compensation

Dharwad: Holding a Hubballi-based private hospital and its doctors guilty of medical negligence while taking care of a newborn baby, the District Consumer Disputes Redressal Commission, Dharwad has directed them to pay Rs 10 lakh as compensation to the victim’s family.

It was alleged by the complainants that the newborn suffered severe burns as the attendant dipped the baby in hot water while giving a sponge bath. 

“OP No.1 to 4 are jointly and severally held liable to answer the claim of complainant and they have been directed to pay Rs.10,00,000/- (Ten lakh only) as damages by way of compensation to the victim child of the complainant within one month from the date of this judgment,” ordered the consumer court.

The matter goes back to 2019 when the complainant’s wife got admitted at the treating hospital for delivery and gave birth to a female child. Allegedly, the baby was healthy, after delivery. However, before the discharge, the attendant took the child for a sponge bath and while doing so, she dipped the child in hot water. Reacting to this, the baby cried and passed motion. Therefore, the baby suffered severe burn injuries on the lower part of the body and the attendant started rubbing the child where the skin was burnt.

Allegedly, the attendant panicked and without any thought peeled the burnt skin of the child and due to such peeling flesh was visible over the buttock and other surrounding area where the hot water touched the child.

The complainants admitted the baby for treatment at the same hospital and the treating doctors suggested that the baby could have epidermolysis bullosa (EB), a rare condition that makes skin fragile and causes blisters on it easily. Consequently, the child remained in treatment at the hospital for 3-4 days and the treating doctor advised the complainant for Genetic Tests on the child at centre for human genetics at Bengaluru.

However, the parents were not convinced by the opinion. Therefore, after getting discharged from the hospital, they admitted the baby to SDM College of Medical Sciences and Hospital in Dharwad.

It was submitted by the complainant that the child remained under treatment at SDM Hospital for around 7 days and by the time of discharge, the burn was already healing. They further submitted that they spent a lot of money on the treatment of the child. On the other hand, the incident caused immense physical and mental agony to the family. 

Further, the complainant argued that the doctors gave the wrong opinion saying that the child had EB. This resulted in more pain, fear and mental agony for the family members.

On the other hand, the doctors and the hospital denied the allegations of negligence. They submitted that the staff brought lukewarm water and washed the baby and during the process, the skin of the baby got discolored and started peeling. Consequently, the dermatologists opined that the peeling of the skin could be due to EB. To confirm the same, the doctor advised the baby’s skin biopsy.

While considering the matter, the consumer court perused the medical literature related to EB and noted that it was an incurable disease but could be managed by proper treatment. 

Further going through the medical history, the commission noted that the child was alright after birth and it was only before discharge when the child started having the problem when the attendant dipped the baby’s buttock in hot water to clean the motion. 

Perusing the discharge summary of the SDM Hospital, the consumer court noted, “In the entire medical records of SDM hospital the issue of E.B. was not raised by the treated doctors.” The Commission further observed that the discharge summary and other records showed that after such treatment for burn injuries the child was alright and the parents had no grievance of re-occurrence of such problem in the child.

The child, who is now 4+ years of age, was present before the Commission, which noted movements and scars noticeable on the victim child. Therefore, the Commission opined that E.B. was not the problem with the victim child since the skin peeling problem started only when the child was immersed by the Attendant in hot water.

“…we have personally saw the victim child as a healthy Baby without any symptoms of either peeling of skin or other skin related problem like EB. Where as in case of EB the affected person has to undergo trauma throughout the life. But it is not the situation in the case of victim child,” noted the consumer court.

Therefore, the Commission termed it as a “classic example of medical negligence”.

“On the basis of the discussion made… we are of the opinion that it is a classic example of medical negligence of Aayya,. Inspite of such glairing negligence and mistake committed by Aayya OP No.1 to 4 being in charge of treatment and administration of oP No.1 city clinic ought to have consoled the complainant, his wife who are the parents of the victim child by giving proper treatment to the burn injuries. Instead of doing so they have tried to colour it as E.B. which is a stigma to the victim child and made the parents of the child to suffer mentally, physically and financially,” opined the Commission.

Therefore, the Commission directed the hospital, its two administrators and the wife of one of the administrators to pay Rs 10 lakh as compensation. “Out of it by way of indemnification, OP No..9 insurance company shall pay Rs.7,50,000/-(Seven lakh fifty thousand only) towards their @75% of the liability and they have to deposit the same within one month from the date of this judgment. Remaining @25% i.e. at Rs.2,50,000/-(Two lakh fifty thousand only) shall be paid by the OP No.1 to 4 within one month from the date of this judgment,” it ordered.

To view the judgment, click on the link below:

https://medicaldialogues.in/pdf_upload/dharwad-district-commission-232944.pdf

Also Read: Hyderabad: Man dies during smile enhancement surgery, Dental clinic booked under IPC 304 A

Powered by WPeMatico

Nintedanib Reveals Remarkable Efficacy in Alleviating Progressive Pulmonary Fibrosis Symptoms

In the groundbreaking INBUILD trial, researchers discovered that nintedanib
can significantly improve the lives of patients suffering from progressive
pulmonary fibrosis (PPF). Nintedanib
holds promise not only in reducing the progression of dyspnea, fatigue, and
cough but also in mitigating the overall impact of ILD over 52 weeks in
patients grappling with PPF.

The trial results were published in the journal European Respiratory Journal

Pulmonary fibrosis, a
condition characterized by scarring of the lungs, often leads to symptoms such
as dyspnea (shortness of breath) and cough, profoundly impacting patients’
daily lives. Hence, researchers conducted a trial, that focused on the effects
of nintedanib on PPF symptoms using the Living with Pulmonary Fibrosis (L-PF)
questionnaire to assess changes in patients’ conditions.

The trial included 663 patients with fibrosing interstitial lung
disease (ILD), excluding idiopathic pulmonary fibrosis, but with more than 10%
lung involvement on high-resolution computed tomography (HRCT) scans and
evidence of ILD progression within the past 24 months. Patients were randomly
assigned to receive either nintedanib or a placebo, with researchers analyzing
L-PF questionnaire scores from baseline to week 52 using mixed models for
repeated measures.


Findings:         

  • The results revealed a significant positive
    impact of nintedanib on patients’ lives compared to the placebo group.
  • Those receiving nintedanib experienced smaller
    increases (worsenings) in adjusted mean L-PF questionnaire total scores (0.5
    versus 5.1) at week 52.         
  • This trend was also observed in symptom scores
    (1.3 versus 5.3), dyspnea (4.3 versus 7.8), and fatigue (0.7 versus 4.0).          
  • One notable finding was the decrease in L-PF
    questionnaire cough score in the nintedanib group, in stark contrast to the
    placebo group where cough scores increased (-1.8 versus 4.3).          
  • Additionally, the impacts of ILD, as assessed
    by the L-PF questionnaire impact score, decreased slightly in the nintedanib
    group while increasing in the placebo group (-0.2 versus 4.6).       
  • These positive outcomes were consistent across
    different patient subgroups, including those with a usual interstitial
    pneumonia-like fibrotic pattern on HRCT and those with other fibrotic patterns
    on HRCT.


The findings suggest that nintedanib has the potential to not only
reduce the worsening of dyspnea, fatigue, and cough but also mitigate the
overall impact of ILD over 52 weeks in patients with progressive pulmonary
fibrosis.

This breakthrough offers hope to individuals grappling with the
debilitating effects of pulmonary fibrosis, as it paves the way for improved
treatment strategies and enhanced quality of life for those affected by this
challenging respiratory condition. As researchers continue to unravel the
complexities of pulmonary fibrosis, advancements like these represent a
significant step forward in the pursuit of better therapeutic options and
increased well-being for patients.

Further reading: Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. DOI: 10.1183/13993003.00752-2023

Powered by WPeMatico